【摘要】 目的研究和评价重组人白细胞介素-Ⅱ(IL-2)辅助治疗肺结核的临床效果。方法选痰菌阳性复治肺结核43例,观察组22例,采用2HL2AK(E)Z(TH)V+IL-2/1HL2(TH)V+IL-2/5HL2V方案化疗;对照组21例,采用2HL2AK(E)Z(TH)V/1HL2(TH)V/5HL2V方案化疗。结果完成疗程可评价疗效者40例,其中观察组20例,对照组20例,观察组痰菌阴转、病灶吸收、空洞的缩小和闭合以及免疫检测结果均优于对照组。无严重不良反应发生。结论重组人IL—2有辅助治疗肺结核的作用,可加速结核菌阴转速度,促进病灶吸收,提高机体免疫力,是安全可靠的生物制剂。更多还原

【Abstract】 Objective To study and evaluate the clinical effects of adjunctive immunotherapy with recombinant human IL-2 in adults with retreatment pulmonary tuberculosis. MethodForty-three sputum smear positive retreatment TB patients were enrolled into this study. There are 22 cases in intervention group and 21 cases in control group. The chemotherapeutic regime which was 2HL2AK(E)Z(TH)V+IL-2/1HL2(TH)V+IL-2/5HL2V in intervention group and 2HL2AK(E)Z(TH)V/1H L2(TH)/5HL2V in control group. ResultForty patients completed the treatment course, their outcome were evaluated. Among of them, 20 patients from intervention group and 20 patients from control group. The sputum smear-conversion, lesion absorbed, cavity shrunk and immune test results in intervention group were better than that of control group. There were no severe side-effects among patients received IL-2 for treatment. ConclusionThe study suggest that the recombinant IL-2 would be not only a safe biological agent, but also an adjunctive immunotherapy for retreatment pulmonary tuberculosis, which can facilitate smear , lesion absorbed, immunity of patients with pulmonary tuberculosis.更多还原